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Abstract 
A 24-year old woman with multisubstance use since the age of 13, including opioids and cocaine, and long-standing 
HIV/HCV seropositivity status, presented with psychosis, agitation, and insomnia at the emergency department of a 
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university hospital. She had been abusive and physically aggressive frequently without specific reasons and was 
involved in criminal legal cases. She was hospitalized twice. During her first hospital stay she experienced a brief 
episode of detachment from her environment, similar to episodes reportedly suffered at home. Psychosis had 
developed following heavy polysubstance abuse. Her mother provided sachets containing benzylglycinamide, a 
substance with no known psychotropic effects, which were also present in the patient’s urine. She was occasionally 
positive for cannabinoids. She used to buy various novel psychoactive substances (NPSs) from the internet and used 
experimentally various substances freely made available to her by drug suppliers/dealers.  She was unable to explain 
clearly why she was taking any of the identified NPS. She stated she was taking benzylglycinamide to calm her when 
smoking synthetic cannabinoids. While it appears that benzylglycinamide is not likely to constitute a novel drug of 
abuse, her polysubstance use exemplifies trends in NPS use patterns among the youths in the Western world and 
should alert mental health workers as to the possible dangers of such behavior and its reflection on social behavior 
and psychopathology. 
 
Key words: New Psychoactive Substances; Drug abuse; Benzylglycinamide; Drug-induced psychosis; HIV infection; 
HCV infection 
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1. Introduction. 
Benzylglycinamide is virtually absent in the medical literature, save for two papers, one not relevant and another 
dealing with the antiepileptic properties of glycine amide derivatives, which found N’-benzylglycinamide to be 
inactive in mixed-breed dogs (Sussan, Dagan, Blotnik, & Bialer, 1999). Extending our PubMed strategy to 
((glycineamide OR glycinamide OR "glycine amide" OR "benzyl glycinamide" OR benzylglycinamide) AND (addiction 
OR abuse OR mental OR brain)) NOT (prolyl-leucyl-glycinamide OR Pro-Leu-Gly OR PLG OR MIF-I OR melanocyte) 
yielded 72 papers as of August 25, 2015, six of which were of some relevance. Glycinamide has been found to 
facilitate NMDA receptor activity (Rao, Cler, Emmett, Mick, Iyengar, & Wood, 1990), to induce antinociception 
(Beyer, Komisaruk, González-Flores, & Gómora-Arrati, 2013) in rodents, and to oppose the effect of dizocilpine, a 
NMDA channel inhibitor, similarly to clozapine in rabbits (Hoffman & Basurto, 2014). Given that its effect on the 
NMDA receptor is opposite to that of the abused drugs ketamine and phencyclidine, it would be surprising that it 
could be abused. The cerebral effects of benzylglycinamide have still to be investigated. 
We describe the case of a young woman with human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) 
infections, who had multisubstance use and subsequently developed psychosis and who used N’-benzylglycinamide 
as a complementary recreational substance. The patient had purchased the substance through the internet and her 
biological fluids were positive for the drug. Asked why she used the drug, she could recall only poorly that it helped 
her to calm down. This case may exemplify the changing pattern of drug use in young people in the Western world. 
2. Case presentation.  A woman aged 24 was brought 31 months ago to the emergency department (ED) of our 
hospital with psychomotor agitation, dysphoria, accelerated and pressured speech, aggression, insomnia with 
impaired sleep-wake cycle, emotional instability, irritability, and rage bouts. She was not delusional. She was under 
juridical restriction at that time. At the ED screening (consisting of a urine immunofluorescence assay seeking 
paracetamol, amphetamine, methamphetamine, barbiturates, benzodiazepines, cocaine, methadone, opiates, 
phenylcyclidine, tetrahydrocannabinol, and tricyclic antidepressant drugs) she was positive for cannabinoids in her 
urine. 
She was voluntarily admitted to our psychiatric facility, but left the ward four days. Her diagnosis was substance 
abuse, unspecified, and substance-related mood disorder. Since she was positive for human immunodeficiency virus 
(HIV), we confirmed her efavirenz/emtricitabine/tenofovir combination and started her on aripiprazole, 15 mg/day, 
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and promazine, 30 mg/day. She was referred back to the Community Drug Abuse service, where she was being 
followed-up. 
Her clinical history was unremarkable; her 5-years-older sister had used drugs since the age of 12. Her parents had 
divorced when the patient was 8 years old; the two sisters went to live with their mother. Her father was emotionally 
detached and showed poor rapport with family members. She started occasional cannabis abuse at age 13, but one 
year later she was abusing it continuously. As a result she impaired important social relationships and suffered 
educational failure. She subsequently quit cannabis and started abusing alcohol, cocaine, and amphetamines. Her 
abuse was most intense during rave parties, which she strongly pursued. Once, at age 16, after having disappeared 
for two days, she was found living with a convicted drug smuggler in poor hygienic conditions. During this period she 
also abused intravenous heroin and was convicted of robbery. When she was 17 she was admitted to a dual 
diagnosis facility of a psychiatric hospital, where she stayed for three months. She was diagnosed as having 
substance use disorder (heroin) and hepatitis virus C infection (HCV). As soon as she reached adult age, she asked to 
be discharged against her doctors’ advice and left the hospital at her own will. She quit school and after one year of 
substance abuse, sexual promiscuity, and law-breaking events, at age 19 she joined a substance detoxification 
community, where she stayed for one year and followed detoxification programs, with little benefit. She returned 
home and received a HIV diagnosis. As a consequence, she was treated at age 20 with 
efavirenz/emtricitabine/tenofovir. She had not given-up her multisubstance use, but rather extended it by smoking 
synthetic cannabinoid preparations. 
On 15 May 2013 she returned to the ER, with severe insomnia, a clinical picture similar to the one of her first 
presentation, but during this second hospitalization she was also delusional and persecutory. She stayed for one 
week and was treated with 2 mg/day risperidone, gabapentin 900 mg/day, clonazepam, 4 mg/day, and the 
antiretroviral drug combination 25 mg rilpivirine, 200 mg FTC (emtricitabine), and 245 mg tenofovir. Her delusions 
had subsided by her discharge. In July 2013 she was twice hospitalized elsewhere after two distinct episodes of 
“speedball” overdose (intravenous heroin and cocaine), that had caused her loss of consciousness. In both cases she 
quit the hospital after a brief stay. 
During August 2013, her mother reported she had been unresponsive in a couple of instances, fixing a remote point 
with her gaze and remaining mute. Episodes lasted 5-10 minutes each. She retained no memory of these episodes of 
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apparent absence. On September 12, 2013, she was referred with a request for compulsory psychiatric admission to 
the emergency room of our hospital. She was accompanied by her mother and showed reduced emotional 
expression, dysphoria, and restlessness; she was oppositional and loquacious, with accelerated speech. The patient 
was in a home confinement status after an arrest for an incongruent car robbery attempt. She eventually accepted 
hospitalization in our psychiatric ward. In the last few days before being proposed for compulsory hospitalization, 
she had been emotionally unstable, aggressive, persecutory, suspicious, and had bizarre thinking (she had pled for 
being forgiven by her mother because she had to change her sex after being imposed to do so by unspecified 
individuals). 
During this hospitalization she denied using any drug and was negative on standard screening. Despite that, she had 
a five-minute episode of unresponsiveness while dining. Neurological examination and standard and sleep-deprived 
EEG showed no abnormality. Magnetic resonance imaging of the brain showed right frontal and parietal subcortical 
glial foci, which were non-specific and of unclear significance. We suspected that these “absence” episodes could be 
due to illicit drug use and informed her mother, who brought us sachets of white powder that her daughter was 
hiding in her room. We obtained blood and urine samples which we sent with the sachets to the Pavia Poison Control 
Centre, the clinical-toxicological coordinating Centre of the National Early Warning System (N.E.W.S), in collaboration 
with the Department of Anti-Drug Policies, Italian Government, Presidency of the Council of Ministers, Rome, Italy. 
However, the patient denied using any drug. The advanced 2nd-level targeted and non-targeted analysis consisted of 
liquid and gas chromatography/mass spectrometry (LC-MS and GC-MS) to search in urine for atropine, scopolamine, 
methoxetamine, ketamine and its metabolite norketamine, butylone, mephedrone, methylenedioxypyrovalerone 
(MDPV), dimethylcathinone, buphedrone, ethcathinone, 4-fluoro-methcathinone, pentedrone, methedrone, 
ethylone, pentylone, 1-Naphyrone, 4-methylethylketone (4-MEC), levamisole, 4-fluoro-amphetamine (4-FA), p-
methoxetamine (PMA), methylenedioxyaminoindane (MDAI), p-methoxymethamphetamine (PMMA), aminopropyl 
benzofuran isomers (5/6 APB), dimethyltryptamine (DMT), 4-bromo-2,5-dimethoxyphenylethylamine (2-CB), 4-iodo-
2,5dimethoxyphenylethylamine (2C-I), 2,5-dimethoxy-4-propylthiophenylethylamine (2C-T-7), and 2,5-dimethoxy-4-
bromoamphetamine (DOB). Screening for synthetic cannabinoids in blood was performed with LC-MS and regards 
the following: JWH-007, JWH-016, JWH-018, JWH-019, JWH-073, JWH-081, JWH-098, JWH-122, JWH-147, JWH-200, 
JWH-250, JWH-302, JWH-398, RCS-4, RCS-8, AM-2201, MAM 2201, AM-2233, WIN-55212, WIN-48,098, and AM-694. 
The laboratory analysed the sachets and found benzylglycinamide. 
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She improved and was discharged after 20 days of hospitalization with 4 mg/day risperidone, lorazepam, 5 mg/day, 
and her previous antiretroviral drug treatment. She was transferred to a drug rehabilitation community by decision 
of the probate judge; she managed to escape after a two-month stay. Meanwhile, the Pavia Centre confirmed the 
presence of benzylglycinamide in patient’s urine, while her blood sample was free from synthetic cannabinoids and 
other substances. 
She eventually returned home in December 2013 where she discontinued all medications, resuming heavy 
cannabinoid, heroin, and alcohol use. She was well for one month, but in February 2014 she manifested incongruent 
behavior, with bizarre and sexual delusions (she masturbated compulsively to turn her menses back, while she 
believed she could become pregnant only if a penis could penetrate in her coccygeal cyst), and probable auditory 
hallucinations (speaking alone). Her mother would later tell us that during this period she frequently visited internet 
sites to seek NPSs. She accessed the ED twice due to agitation (3 and 28 of March, 2014), subsequently running 
away. Her urine was positive for cannabinoids, paracetamol, and opiate derivatives the first time and for 
cannabinoids only, the second time. 
She became increasingly aggressive and was sentenced to further two months of imprisonment for robbery. 
Nevertheless, she continued staying at home, where she destroyed a wardrobe and was verbally and physically 
aggressive towards her mother. She was persuaded by her mother to re-establish contact with the local mental 
health department, but on 3 of April she assaulted a bystander, causing him a zygomatic bone fracture. The Police 
arrested her and brought her compulsorily to the ED; subsequently she was hospitalized in our psychiatric 
department. On her arrival she was mute, with psychomotor retardation, and progressively became oppositional, 
hostile, and eventually aggressive. We administered 5 mg risperidone, 2 mg desmethyldiazepam, 60 mg promazine, 
and reintroduced her previous anti-retroviral drug combination, despite her suspiciousness about it (she delusionally 
believed that the drug was made of eggshells that could harm her). At both ED and Pavia toxicological screenings she 
was clean for all drugs. When asked to respond why she took benzylglycinamide, for which she was found to be 
positive in urine on the previous occasion, she admitted having purchased the substance via the internet and that 
she was mixing it with tobacco to dull her senses. She could not recall exactly to which extent she obtained the 
desired effect. Her mother came with a bag full of glass vials and bottles with various powders which she said she 
found at home in a hidden place and which she reported that her daughter was mixing with normal tobacco and 
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marijuana. Bottles and vials were labeled with the chemical formula and production date (Figure 1). The patient told 
us she obtained them through the internet. We obtained her blood and urine samples and sent them together with 
the contents of the bottles to the Pavia Centre and to ADT, asking them to control whether the formulas and 
declared substances corresponded with the bottles’ contents. ADT found bottles to contain different drugs, pro-
drugs or by-products (Table 1) not corresponding to the labels. 
She was discharged after a 21-day hospitalization with a diagnosis of ICD-9 “drug-induced delusional syndrome”, 
roughly corresponding to DSM-5 substance-induced psychotic disorder, and with a prescription of 5 mg risperidone, 
2 mg desmethyldiazepam, and the aforementioned anti-retroviral drug combination. Her probate judge ordered her 
to join a drug rehabilitative community in Turin, Northern Italy, where the patient awaited her trial. She remained 
there for about six months, until the end of her sentence. She returned home and suspended all drug treatment, 
included antiretroviral therapy. The patient went on to develop persecutory and bizarre delusions and became 
aggressive towards her mother in about two months. She was brought to the ED by the police and was subsequently 
compulsorily hospitalized in our department in January 7, 2015. Her toxicological analyses (blood and urine samples 
were collected and sent again to the Pavia Poison Control Centre) yielded no significant results. She stated she was 
no longer using any type of recreational drug. We prescribed paliperidone palmitate injections, 100 mg/30 days, 2.5 
mg/day oral lorazepam, and 15 mg/day promazine in oral drops and reinstituted her antiretroviral regimen. During 
her hospital stay, her mother told us that her daughter was using experimental drugs that pushers were sending her 
freely to test the possible psychotropic effects of chemical synthesis drugs. This may explain why the patient could 
not give us an account of the bottles’ content and also why she took drugs that produced no concrete psychotropic 
effect. At discharge she had improved, delusions were absent, but mood was dysphoric. Her CD4+/CD8+ ratio was 
within normal limits. She was sent back to the rehabilitative community, where she currently resides and is 
reportedly doing well. She and her mother signed free, informed consents for case publication. 
3. Discussion 
Novel psychoactive substance (NPS) use constitutes a new social behavioral pattern. It is facilitated by private 
chemical laboratory proliferation producing a host of novel substances to slip between legislative amendments and 
be sold legally until discovery of their abuse potential and subsequent regulation. People prone to experiment with 
NPS were termed “psychonauts” after Jünger’s description of Arthur Heffter’s behavior, a pharmacologist who had 
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described the effects of the newly discovered mescaline (Heffter, 1896) and peyote (Heffter, 1898) after having them 
tried himself. The spread of this recreational drug use pattern has as yet unknown social and individual effects, but 
for many connoisseurs of the issue, it bears a considerable threat potential (Schifano, 2001; Sacco & Finklea, 2014; 
Schifano, Orsolini, Papanti, & Corkery, 2015). Psychonauts are likely to engage in multiple substance use, without 
sticking to a particular drug. Our patient apparently abused drugs that are not likely to induce any particularly 
desirable effect that she knew from before. Her mother’s suspicion was that her daughter was exploited by drug 
suppliers/dealers to probe the effects of unknown, experimental synthetic drugs. Her psychosis, mood instability, 
and uncontrollable impulsiveness, all secondary to compulsive substance abuse, combined with the threatening 
nature of HIV infection, rendered her vulnerable to exploitation. The patient used benzylglycinamide with no specific 
aim, just to test its possible effects. Her behavior, with her deliberate law infringement, her instability in accepting 
state-provided care, and her prompt abandonment of communities or hospitals, frame a background against which 
these new trends in drug use have to be viewed. The fact that she stored many vials containing substances with 
variable or questionable dependence/abuse-inducing potential may be taken to mean she was trying to modulate 
the effect of other drugs of abuse she was taking. 
Among the drugs she possibly used (Table 1) concomitantly with synthetic cannabinoids and benzylglycinamide, 
none can be attributed the responsibility for her brief episodes of apparent detachment from environment. 
However, intake of no drug in Table 1 was consistent with the development of dissociative symptoms. Owing to their 
mechanisms, 4-piperidinone and 1H-indol-2-carboxylic acid could be related to anticonvulsant activity rather than 
seizures. Whether the detachment occurred due to the use or withdrawal of a given NPS is unclear, but the short 
half-time of benzylglycinamide (about 35 min in dogs and less than 1 hour in rats; Sussan et al., 1999) is unlikely to 
account for dependence or withdrawal. Dibenzylpiperazine, but not benzylglycinamide, could have been responsible 
for psychosis. 
4. Conclusion 
We described the use of benzylglycinamide in a patient with multisubstance abuse, HIV/HCV infection, and 
psychosis. The purpose of benzylglycinamide use cannot be probed, due to patient uncooperativeness. The 
possibility that similar patients may be at risk for being the experimental subjects of amoral drug suppliers/dealers 
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and other unlawful people should caution physicians to investigate these issues and raises heretofore 
unprecedented social issues. 
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Figure caption 
 
Figure 1. Bottles the patient purchased from internet sources, whose labels displayed chemical structures of 
substances claimed to be contained in them. 
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Table 1. Substances found in patient’s bottles. 
Substance Chemical structure Class/Mechanism Commonly used in: 
Dihydronor-
morphinone 
 
μ-opioid ligand No known application; 
derivatives may possess 
analgesic properties 
1H-Indol-2-
carboxylic acid 
 
Probably blocks NMDA 
glutamate receptors at their 
glycine sites 
No known application; 
potential anti-obesity 
agent; putative anti-
stroke, anti-head injury, 
anti-dementia and 
analgesic activity 
1-(4-Methoxy-
phenyl)ethanone 
 
A terpene, may have activity 
on CB receptors 
Cigarette cutting and 
flavoring in foodstuff 
Quinoline 
 
Prevents polymerization of 
toxic haem by forming a 
complex with haem, thus 
terminating chain extension 
Cigarette additive, 
production of dyes, used 
in preparation of other 
chemicals; contained in 
anti-malarial agents 
Dibenzothiophene 
 
Heterocyclic derivative of 
polycyclic aromatic 
hydrocarbon, an agonist to 
the aryl hydrocarbon 
receptor 
Used in cosmetics and 
pharmaceuticals; product 
of coal combustion 
α-Methyl-m-
trifluormethyl-
Phenethylamine 
(Norfenfluramine)  
Stimulant; calcium-
independent 5-HT/NA 
releaser, potent 5-HT2A, 5-
HT2B, and 5-HT2C agonist 
Appetite suppressant 
Stephabyssine 
 
Stephania abyssinica 
morphine and 
morphinandienone alcaloid, 
μ-opioid ligand 
The plant is used as a 
folk remedy to treat 
asthma, tuberculosis, 
dysentery, 
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hyperglycemia, malaria 
and other conditions 
Stephaboline 
 
Stephania abyssinica 
morphine and 
morphinandienone alcaloid, 
μ-opioid ligand 
Same as above 
Hexanoic acid 
(caproic acid) 
 
Carboxylic acid; fibrinolysis 
inhibitor; facilitates passage 
of insulin through mucosal 
epithelia 
Component of vanilla; 
used as flavoring agent 
in butter, milk, cream, 
strawberry, bread, beer, 
and nut flavors 
Docosahexaenoic 
acid 
 
Polyunsaturated ω3 fatty 
acid; conjointly with uridine 
and choline, ↑ synthesis and 
levels of phosphatides and 
pre- and postsynaptic 
proteins, and ↑ formation of 
dendritic spines  
Diets, cognitive decline, 
prodromal states 
β-Carotene 
 
Provitamin A, terpenoid 
hydrocarbon, nonpolar, fat 
soluble vitamin with 
antioxidant activity when 
beta-carotene 15,15’-
monooxygenase converts it 
to retinol, which binds 
nuclear receptors and affects 
gene expression 
Vitamin A deficiency 
may lead to 
keratomalacia, loss of 
night vision, 
xerophthalmia and other 
ocular conditions and 
supplements are used to 
contrast them; other 
medical uses include 
hepatic failure and 
porphyrias 
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Ethyl-iso-
allocholate 
 
A steroid from Cenchrus 
ciliaris; acts through nuclear 
steroid receptors 
Biliary acid oil 
emulsifier 
Octadecatrienoic 
acid 
 
ω3 Fatty acid; enhances 
choline acetyltransferase 
activity and ↑social 
interaction in post-weaning 
mice; antioxidant; 
antithrombotic activity? 
Dietary 
Benzoylamino-
hexanoic acid 
 
Carboxylic acid; derivatives 
inhibit mitotic centromere-
associated kinesin (MCAK) 
ATPase activity; probable 
cytostatic activity (tumor 
growth and cell cycle 
progression and 
endoreduplication) 
No particular use 
Dihydrotestosterone 
 
Androgenic steroid; acts 
through nuclear receptors to 
affect DNA expression; may 
cause male baldness and 
benign prostatic hyperplasia 
and increase aggression 
Body building 
N-acetyl-Valine 
 
Amino acid Product of acetylation of 
an L-amino acid used in 
the synthesis of 
pharmaceuticals 
Ethylhydrazone 
 
Aldehyde Organic pollutant. No 
medical or industrial use 
Pentanamine 
 
Amine, possible stimulant Flavoring agent used as 
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a solvent and in the 
manufacture of dyes, 
emulsifiers, and 
pharmaceuticals 
Dibenzylpiperazine 
 
Piperazine derivative often 
found as an impurity in the 
recreational stimulant drug 
benzylpiperazine (BZP); 
when combined with 
MDMA may induce 
psychosis or death 
Stimulant, recreational 
4-Piperidinone 
 
Piperidinone (piperidine 
derivative); curcumin 
analogue, may be cytostatic. 
2-Piperidinone potentiates 
GABAA-mediated currents 
and may be anticonvulsant 
Intermediate in the 
manufacture of 
chemicals and 
pharmaceutical drugs 
(e.g., fentanyl) 
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Highlights 
 Benzylglycinamide (BGA) has never been reported as a drug of abuse 
 We report on a patient with psychosis with documented BGA abuse 
 Patient claimed that the addition of BGA to cannabinoids helped her to calm 
